(Q46504597)

22 December 2017

title

Population pharmacokinetic analysis of indinavir in HIV-infected patient treated with a stable antiretroviral therapy (English)

1 reference

22 December 2017

1 reference

1 reference

5

Cécile Goujard

1 reference

22 December 2017

Anne-Marie Taburet

3

object named as

Anne-Marie Taburet

1 reference

22 December 2017

France Mentré

6

object named as

France Mentré

1 reference

22 December 2017

author name string

Karl Brendel

1

1 reference

22 December 2017

Mayeule Legrand

2

1 reference

22 December 2017

Gabriel Baron

4

1 reference

22 December 2017

Cophar 1-ANRS 102 Trial Group

7

1 reference

22 December 2017

publication date

1 June 2005

1 reference

22 December 2017

Fundamental and Clinical Pharmacology

published in

1 reference

22 December 2017

volume

19

1 reference

22 December 2017

issue

3

1 reference

22 December 2017

page(s)

373-383

1 reference

22 December 2017

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2005.00315.X

Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2005.00315.X

Long-term efficacy and safety of ritonavir/indinavir at 400/400 mg twice a day in combination with two nucleoside reverse transcriptase inhibitors as first line antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2005.00315.X

Correlation between reduction in plasma HIV-1 RNA concentration 1 week after start of antiretroviral treatment and longer-term efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2005.00315.X

Drug resistance and predicted virologic responses to human immunodeficiency virus type 1 protease inhibitor therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2005.00315.X

Nevirapine or lamivudine plus stavudine and indinavir: examples of 2-class versus 3-class regimens for the treatment of human immunodeficiency virus type 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2005.00315.X

Determination of indinavir and nelfinavir trough plasma concentration efficacy thresholds according to virological response in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2005.00315.X

Pharmacokinetic profile and tolerability of indinavir-ritonavir combinations in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2005.00315.X

Continued indinavir versus switching to indinavir/ritonavir in HIV-infected patients with suppressed viral load

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2005.00315.X

Plasma population pharmacokinetics and penetration into cerebrospinal fluid of indinavir in combination with zidovudine and lamivudine in HIV-1-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2005.00315.X

Indinavir population pharmacokinetics in plasma and cerebrospinal fluid. The HIV Neurobehavioral Research Center Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2005.00315.X

Indinavir-based treatment of HIV-1 infected patients: efficacy in the central nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2005.00315.X

Population pharmacokinetics and pharmacodynamics of efavirenz, nelfinavir, and indinavir: Adult AIDS Clinical Trial Group Study 398.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2005.00315.X

Determination of indinavir in plasma by solid-phase extraction and column liquid chromatography.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2005.00315.X

Sensitive and rapid method for the simultaneous quantification of the HIV-protease inhibitors indinavir, nelfinavir, ritonavir, and saquinavir in human plasma by reversed-phase liquid chromatography

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2005.00315.X

Ways to fit a PK model with some data below the quantification limit

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2005.00315.X

HIV-1 protease inhibitors are substrates for the MDR1 multidrug transporter.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2005.00315.X

Interaction of anti-HIV protease inhibitors with the multidrug transporter P-glycoprotein (P-gp) in human cultured cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2005.00315.X

Population pharmacokinetics of nevirapine in an unselected cohort of HIV-1-infected individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2005.00315.X

Population pharmacokinetics of thioTEPA and its active metabolite TEPA in patients undergoing high-dose chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2005.00315.X

The importance of modeling interoccasion variability in population pharmacokinetic analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2005.00315.X

Therapeutic drug monitoring in HIV infection: current status and future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2005.00315.X

Therapeutic drug monitoring of nelfinavir and indinavir in treatment-naive HIV-1-infected individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2005.00315.X

10.1111/J.1472-8206.2005.00315.X

21 January 2018

Identifiers

DOI

1 reference

22 December 2017

1 reference

22 December 2017